Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | YES1 | P07947 | 1/20 | 0.40 |
| ▸ | LYN | P07948 | 1/20 | 0.40 |
| ▸ | HCK | P08631 | 1/20 | 0.40 |
| ▸ | FGR | P09769 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.40 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL922903 | 1.00 | PLK4 (0.44) | PLK4NCF1JAK2JAK3KDR | |
| SCHEMBL27608274 | 0.88 | HRH3 (0.42) | PLK4JAK2NOS1SMN1; SMN2CDK5 | |
| SCHEMBL921373 | 0.88 | NCF1 (0.51) | PLK4NCF1JAK2JAK3KDR | |
| SCHEMBL923105 | 0.80 | NCF1 (0.44) | PLK4NCF1JAK2JAK3NOS1 | |
| SCHEMBL922630 | 0.80 | NCF1 (0.44) | PLK4NCF1JAK2JAK3KDR | |
| SCHEMBL922631 | 0.80 | NCF1 (0.44) | PLK4NCF1JAK2JAK3KDR | |
| SCHEMBL923104 | 0.80 | NCF1 (0.44) | PLK4NCF1JAK2JAK3NOS1 | |
| SCHEMBL921970 | 0.78 | PRMT6 (0.48) | JAK2JAK3ALDH1A1SMN1; SMN2CDK5 | |
| SCHEMBL924459 | 0.77 | PRMT6 (0.47) | JAK2JAK3ALDH1A1SMN1; SMN2CDK5 | |
| SCHEMBL923229 | 0.75 | MC4R (0.44) | NCF1JAK2JAK3BTKLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | claimed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | claimed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | claimed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | claimed |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8445694-B2 | Hydrazonopyrazole derivatives and their use as therapeutics | DERMIRA (CANADA), INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | PLK4 101/4885NCF1 1798/4885JAK2 78/4885 |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | PLK4 101/4885NCF1 1798/4885JAK2 78/4885 |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | MKI67, CDK4, CCNC | PLK4 154/4885NCF1 1489/4885JAK2 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.